Details
-
Change Request
-
Resolution: Persuasive with Modification
-
Highest
-
Potential Drug-Drug Interaction (PDDI) (FHIR)
-
0.2.0 [deprecated]
-
Clinical Decision Support
-
Use Case [deprecated]
-
2 Min Info Model 2.1 Definitions of Core Info Items
-
-
Richard Boyce/Isaac Vetter: 9-0-0
-
Enhancement
-
Non-substantive
Description
IG needs to include dosage, route are required for CDS hook. For example, if a drug is given topically, the metabolism route will be different and different organs will be doing the metabolism. This is key to certain circumstances. An example is local application of NSAIDS in patients with cirrhosis due to impaired metabolism/excretion and leads to undertreatment of pain in this population. (https://aasldpubs.onlinelibrary.wiley.com/doi/full/10.1002/cld.711)
Existing Wording:
Drugs Involved Two or more drugs considered to be possible participants in a potential drug-drug interaction\. Drugs may be specified as drug classes, specific chemicals, products, or in any other appropriate level of granularity\. Specification of each drug involved in a PDDI may include the use of a single drug identifier (http://purl\.obolibrary\.org/obo/APOLLO_SV_00000461) from a medical terminology, or a drug concept set identifier (http://purl\.obolibrary\.org/obo/DIDEO_00000128) that identifies two or more relevant drug identifiers\.
Attachments
Issue Links
- is voted on by
-
BALLOT-14220 Affirmative - Vannak Kann : 2020-Sep-FHIR IG PDDI CDS R1 STU
- Closed